ReviewFrontiers in oncology2026
Vulvar malignant melanoma versus vaginal malignant melanoma: distinct biology, distinct clinical behavior, and distinct management?
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant melanoma of the female genital tract is rare but highly aggressive. Vulvar malignant melanomas and vaginal malignant melanomas are commonly grouped as vulvovaginal malignant melanoma because of their anatomical proximity, low incidence, and limited disease-specific evidence. However, accumulating clinical, pathological, and biological observations suggest that this conventional grouping may mask important site-related heterogeneity. Vulvar malignant melanoma arises within a complex mucocutaneous transition zone and may partially overlap biologically with cutaneous melanoma, whereas vaginal malignant melanoma more consistently demonstrates features of mucosal melanoma. These distinctions influence patterns of presentation, local extension, lymphatic dissemination, therapeutic feasibility, recurrence behavior, and survival outcomes. Vaginal malignant melanoma is frequently diagnosed at a more advanced stage because of occult symptoms and challenging local control, contributing to its particularly poor prognosis. In contrast, vulvar malignant melanoma encompasses a broader biological spectrum that may require subsite-specific interpretation. Although both entities belong to the spectrum of lower female genital tract melanoma, emerging evidence indicates that they should not be treated as interchangeable diseases in either research design or clinical management. This review synthesizes current evidence regarding the overlap and divergence between vulvar and vaginal malignant melanoma and advocates for a site-a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.